Research progress in targeted anticancer drug-associated hypertension
ZHANG Min
LI Peng
SHENG Yanhui
Abstract：The Global Cancer Observatory has reported that the global cancer prevalence rate is continuing to increase,with a predicted surge in the number of new cases from 19.3 million in 2020 to 28.4 million in 2040.The advent of molecular diagnostic technology has led to the widespread utilisation of targeted drugs in the precise management of malignant neoplasms.However,a variety of targeted drugs have been associated with elevated blood pressure,new-onset hypertension,or uncontrolled pre-existing hypertension.Therefore,the management of cancer-related hypertension(CR-HTN)has become an important challenge in the comprehensive oncology treatment.This review outlines the common risk factors for tumors and hypertension.It focuses on summarizing the pathophysiological mechanisms through which targeted drugs in CR-HTN contribute to elevated blood pressure via core pathways such as endothelial dysfunction and imbalance in vascular tone regulation.Additionally,it discusses comprehensive management strategies,including risk stratification,dynamic monitoring,lifestyle interventions,and individualized antihypertensive drug selection.The aim is to provide a reference for optimizing cardiovascular risk management in cancer patients in clinical practice.
Keywords：CancerTargeted anticancer drugsTargeted therapyCancer-related hypertensionPathological mechanismsManagement strategies
Publication Date：2026-01-28
Online Publishing Date：2026-03-18(First online date of this platform, not the publication date of the document)
Pages：6( 92-97 )